๐ข ๐๐จ๐ฆ๐ง ๐๐ก: $Novo Nordisk AS(NVO.US) Novo Nordisk's Phase 3 Ziltivekimab Trial Misses Primary Cardiovascular Endpoint
๐ ๐๐ฒ๐ ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐:โค ๐ก๐ผ๐๐ผ ๐ก๐ผ๐ฟ๐ฑ๐ถ๐๐ธ's ๐ญ๐๐จ๐ฆ phase 3 trial failed to reduce ๐ ๐๐๐.โค Hazard ratio was ๐ฌ.๐ต๐ต with a ๐ต๐ฑ% confidence interval of ๐ฌ.๐ด๐ดโ๐ญ.๐ญ๐ญ.โค Trial enrolled more than ๐ฒ,๐ฏ๐ฌ๐ฌ patients with ๐๐ฆ๐๐ฉ๐, ๐๐๐, and elevated inflammation.โค Ziltivekimab reduced ๐๐-๐ฒ and ๐ต๐๐๐ฅ๐ฃ, confirming target engagement.โค Biological improvements did not translate into fewer cardiovascular events.โค Serious infections occurred more frequently with ๐๐ถ๐น๐๐ถ๐๐ฒ๐ธ๐ถ๐บ๐ฎ๐ฏ than placebo.โค No difference in ๐ฎ๐น๐น-๐ฐ๐ฎ๐๐๐ฒ ๐บ๐ผ๐ฟ๐๐ฎ๐น๐ถ๐๐ was observed.โค Novo Nordisk expects a ๐ป๐ผ๐ป-๐ฐ๐ฎ๐๐ต impairment charge in ๐ค๐ฏ ๐ฎ๐ฌ๐ฎ๐ฒ.โค ๐๐๐ฅ๐ ๐๐ฆ and ๐๐ฅ๐ง๐๐ ๐๐ฆ phase 3 trials will continue, with results expected in ๐๐ญ ๐ฎ๐ฌ๐ฎ๐ณ.๐ ๐ช๐ต๐ ๐ง๐ต๐ถ๐ ๐ ๐ฎ๐๐๐ฒ๐ฟ๐:โค Represents a setback for Novo Nordisk's ๐ฐ๐ฎ๐ฟ๐ฑ๐ถ๐ผ๐๐ฎ๐๐ฐ๐๐น๐ฎ๐ฟ drug pipeline.โค Raises questions about whether ๐๐-๐ฒ inhibition alone improves cardiovascular outcomes.โค May shift investor focus toward upcoming ๐๐๐ฅ๐ ๐๐ฆ and ๐๐ฅ๐ง๐๐ ๐๐ฆ trial results.โค Company says ๐ฎ๐ฌ๐ฎ๐ฒ operating profit guidance remains unchanged.๐ ๐๐ ๐ฝ๐ฒ๐ฟ๐ ๐ฆ๐๐ฎ๐๐ฒ๐บ๐ฒ๐ป๐:๐ ๐ฎ๐ฟ๐๐ถ๐ป ๐๐ผ๐น๐๐ ๐๐ฎ๐ป๐ด๐ฒ, Executive Vice President and Chief Scientific Officer at Novo Nordisk:"Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population."The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments